229 related articles for article (PubMed ID: 1707414)
1. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
2. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
4. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.
Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ
Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241
[TBL] [Abstract][Full Text] [Related]
5. Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells.
Wang ZP; Duan GL; Chen YR; Qin DS; Liu GD; Niu HG
Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):276-8. PubMed ID: 10452107
[TBL] [Abstract][Full Text] [Related]
6. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
7. Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.
Ami K; Ohkawa T; Koike Y; Sato K; Habu Y; Iwai T; Seki S; Hiraide H
Clin Exp Immunol; 2002 Jun; 128(3):453-9. PubMed ID: 12109440
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin sensitises fresh transitional carcinoma cells and T24 cell line to non-MHC-restricted cytotoxicity in vitro.
Kaasinen ES; Kalliomäki PH; Alfthan OS; Timonen TT
Br J Urol; 1993 Dec; 72(6):897-906. PubMed ID: 8306153
[TBL] [Abstract][Full Text] [Related]
9. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
10. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
11. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
12. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
[TBL] [Abstract][Full Text] [Related]
13. Changes in natural immunity during the course of HIV-1 infection.
Brenner BG; Gryllis C; Gornitsky M; Wainberg MA
Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673
[TBL] [Abstract][Full Text] [Related]
14. Immunomagnetic isolation of NK and LAK cells.
Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.
Karimine N; Arinaga S; Inoue H; Nanbara S; Ueo H; Akiyoshi T
Clin Exp Immunol; 1994 Jun; 96(3):484-90. PubMed ID: 8004819
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
17. [Natural killer (NK) and lymphokine-activated killer (LAK) activities of a patient recovered from bladder cancer, and the characteristics of LAK cells generated from lymphocyte subsets].
Komatsu F; Kihara K
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Apr; 18(2):197-206. PubMed ID: 7553054
[TBL] [Abstract][Full Text] [Related]
18. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
20. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
